朝药泽兰乙醇提取物对糖尿病胃轻瘫大鼠胃平滑肌纤维化的影响
摘要
目的探讨朝药泽兰乙醇提取物对糖尿病胃轻瘫大鼠胃平滑肌纤维化的影响及机制。方法 SD大鼠以STZ诱导建立1型糖尿病大鼠,饲养6周后随机分为模型组、泽兰高剂量组、泽兰中剂量组和泽兰低剂量组。另以正常大鼠作为对照组。药物组分别按22 g/(kg·d)、11 g/(kg·d)、5.5 g/(kg·d)灌胃泽兰乙醇提取物,模型组与对照组灌胃相同体积无菌蒸馏水,5周后观察各组大鼠一般状态并检测各组大鼠体重、血糖、胃内色素残留率及胃肠推进率,Masson染色法观察各组大鼠胃平滑肌纤维化情况,Western blot法检测各组大鼠胃平滑肌TIMP-2及TGF-β1表达水平。结果各药物组大鼠随药物剂量增加一般状态改善明显、体重增加、血糖下降。胃内色素残留率模型组高于泽兰高、中、低剂量组;泽兰高剂量组低于中、低剂量组。胃肠推进速率模型组低于泽兰高、中、低剂量组;泽兰高剂量组高于中、低剂量组。Masson染色结果发现,模型组高于泽兰高、中、低剂量组;泽兰高剂量组低于中、低剂量组。Western blot结果发现,TIMP-2蛋白相对表达量,模型组高于泽兰高、中剂量组;泽兰高剂量组明显低于中、低剂量组。TGF-β1蛋白相对表达量,模型组高于泽兰高、中剂量组;泽兰高剂量组明显低于中、低剂量组;泽兰中剂量组低于低剂量组。结论朝药泽兰乙醇提取物具有降糖作用,同时对糖尿病胃轻瘫具有缓解功能,其机制可能与抑制胃组织TIMP-2与TGF-β1表达,进而抑制胃平滑肌组织纤维化有关。
引文
[1] Rayner CK,Horowitz M.Gastrointestinal motility and glycemic control in diabetes:the chicken and the egg revisited [J].J Clin Invest,2006,116(2):299.
[2] 周冰,金政,张默函.糖尿病模型大鼠胃平滑肌组织纤维化机制研究[J].延边大学医学学报,2017,40 (4):235.
[3] 杨芳,李敬林,依秋霞,等.益气解毒活络方对早期糖尿病肾病大鼠的防治作用[J].中国实验方剂学杂志,2014,20(11):165.
[4] 宋佰慧,崔昊震,张默函.泽兰乙醇提取物对STZ诱导糖尿病小鼠肾脏的保护作用[J].中国生化药物杂志,2015,35 (5):14.
[5] Mo-han Zhang,Jing-zhi Jiang,Ying-lan Cai,et al.Significance of dynamic changes in gastric smooth muscle cell apoptosis,PI3K–AKT–mTOR and AMPK–mTOR signaling in a rat model of diabetic gastroparesis[J].Mol Med Rep,2017,16(2):1530.
[6] Sha H,Zhao JB,Zhang ZY,et al.Effect of Kaiyu Qingwei Jianji on the morphometry and residual strain distribution of small intestine in experimental diabetic rats[J].World J Gastroenterol,2006,12(44):7149.
[7] Fr kjaer JB,Brock C,Brun J,et al.Esophageal distension parameters as potential biomarkers of impaired gastrointestinal functionin diabetes patients[J].Neurogastroenterol Motil,2012,24(11):1016.
[8] Westermann D,Heymans S.Fibrosis or hypertrophy:let TIMPs decide[J].Cardiovasc Res,2014,103(2):196.
[9] 叶太生,张莹雯,王秀萍.当归补血汤醇提物和水提物调控BMP-7、TGF-β1表达对腺嘌呤诱导的肾间质纤维化大鼠保护作用的比较[J].时珍国医国药,2018,29 (11):2619.
[10] Dalziel JE,Fraser K,Young W,et al.Gastroparesis and lipid metabolism-associated dysbiosis in Wistar-Kyoto rats[J].Am J Physiol Gastrointest Liver Physiol,2017,313(1):G62.
[2] 周冰,金政,张默函.糖尿病模型大鼠胃平滑肌组织纤维化机制研究[J].延边大学医学学报,2017,40 (4):235.
[3] 杨芳,李敬林,依秋霞,等.益气解毒活络方对早期糖尿病肾病大鼠的防治作用[J].中国实验方剂学杂志,2014,20(11):165.
[4] 宋佰慧,崔昊震,张默函.泽兰乙醇提取物对STZ诱导糖尿病小鼠肾脏的保护作用[J].中国生化药物杂志,2015,35 (5):14.
[5] Mo-han Zhang,Jing-zhi Jiang,Ying-lan Cai,et al.Significance of dynamic changes in gastric smooth muscle cell apoptosis,PI3K–AKT–mTOR and AMPK–mTOR signaling in a rat model of diabetic gastroparesis[J].Mol Med Rep,2017,16(2):1530.
[6] Sha H,Zhao JB,Zhang ZY,et al.Effect of Kaiyu Qingwei Jianji on the morphometry and residual strain distribution of small intestine in experimental diabetic rats[J].World J Gastroenterol,2006,12(44):7149.
[7] Fr kjaer JB,Brock C,Brun J,et al.Esophageal distension parameters as potential biomarkers of impaired gastrointestinal functionin diabetes patients[J].Neurogastroenterol Motil,2012,24(11):1016.
[8] Westermann D,Heymans S.Fibrosis or hypertrophy:let TIMPs decide[J].Cardiovasc Res,2014,103(2):196.
[9] 叶太生,张莹雯,王秀萍.当归补血汤醇提物和水提物调控BMP-7、TGF-β1表达对腺嘌呤诱导的肾间质纤维化大鼠保护作用的比较[J].时珍国医国药,2018,29 (11):2619.
[10] Dalziel JE,Fraser K,Young W,et al.Gastroparesis and lipid metabolism-associated dysbiosis in Wistar-Kyoto rats[J].Am J Physiol Gastrointest Liver Physiol,2017,313(1):G62.